Acelrx Pharmaceuticals Stock Working Capital
| ACRXDelisted Stock | USD 1.01 0.01 1.00% |
AcelRx Pharmaceuticals fundamentals help investors to digest information that contributes to AcelRx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of AcelRx Stock. The fundamental analysis module provides a way to measure AcelRx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AcelRx Pharmaceuticals stock.
AcelRx |
AcelRx Pharmaceuticals Company Working Capital Analysis
AcelRx Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current AcelRx Pharmaceuticals Working Capital | 10.8 M |
Most of AcelRx Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AcelRx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, AcelRx Pharmaceuticals has a Working Capital of 10.8 M. This is 97.46% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 99.27% higher than that of the company.
AcelRx Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AcelRx Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AcelRx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing AcelRx Pharmaceuticals by comparing valuation metrics of similar companies.AcelRx Pharmaceuticals is currently under evaluation in working capital category among its peers.
AcelRx Fundamentals
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (28.28) % | |||
| Current Valuation | 3.25 M | |||
| Shares Outstanding | 16.95 M | |||
| Shares Owned By Insiders | 2.63 % | |||
| Shares Owned By Institutions | 38.88 % | |||
| Number Of Shares Shorted | 508.11 K | |||
| Price To Earning | 0.39 X | |||
| Price To Book | 0.74 X | |||
| Price To Sales | 36.65 X | |||
| Revenue | 1.77 M | |||
| Gross Profit | (3.34 M) | |||
| EBITDA | (30.18 M) | |||
| Net Income | 47.76 M | |||
| Cash And Equivalents | 22.92 M | |||
| Cash Per Share | 3.11 X | |||
| Total Debt | 10.42 M | |||
| Debt To Equity | 0.43 % | |||
| Current Ratio | 1.81 X | |||
| Book Value Per Share | 1.08 X | |||
| Cash Flow From Operations | (28.33 M) | |||
| Short Ratio | 4.56 X | |||
| Earnings Per Share | (2.75) X | |||
| Target Price | 4.63 | |||
| Number Of Employees | 19 | |||
| Beta | 0.52 | |||
| Market Capitalization | 13.56 M | |||
| Total Asset | 47.49 M | |||
| Retained Earnings | (425.83 M) | |||
| Working Capital | 10.8 M | |||
| Current Asset | 118.95 M | |||
| Current Liabilities | 12.78 M | |||
| Z Score | -13.56 | |||
| Net Asset | 47.49 M |
About AcelRx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AcelRx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AcelRx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AcelRx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in AcelRx Stock
If you are still planning to invest in AcelRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AcelRx Pharmaceuticals' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges |